Deutsch English Français

Contact

EP1853249

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1853249

EP1853249 - A STABLE PHARMACEUTICAL COMPOSITION COMPRISING A FIXED DOSE COMBINATION OF FENOFIBRATE AND AN HMG-COA REDUCTASE INHIBITOR [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 03.01.2014 Database last updated on 14.06.2024
Most recent event Tooltip	03.01.2014	Application deemed to be withdrawn	published on 05.02.2014 [2014/06]
Applicant(s)	For all designated states Veloxis Pharmaceuticals A/S Kogle Alle 4 2970 Ho̸rsholm / DK
	[2011/34]
Former [2007/46]	For all designated states LifeCycle Pharma A/S Kogle Alle 4 2970 Horsholm / DK
Inventor(s)	01 / HOLM, Per Gro̸ndals Parkvej 54 DK-2720 Vanlo̸se / DK
	02 / NORLING, Tomas Mo̸llevænget 36 DK-2800 Lyngby / DK
	[2007/46]
Representative(s)	Grünecker Patent- und Rechtsanwälte PartG mbB Leopoldstrasse 4 80802 München / DE
	[N/P]
Former [2008/28]	Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät Leopoldstrasse 4 80802 München / DE
Former [2007/46]	Joersboe, Anne-Marie Charlotte H. LifeCycle Pharma A/S Kogle Allé 4 2970 Harsholm / DK
Application number, filing date	06706137.4	10.02.2006
	[2007/46]
	WO2006DK50004
Priority number, date	DK20050000200	10.02.2005 Original published format: DK 200500200
	DK20050000576	20.04.2005 Original published format: DK 200500576
	[2007/46]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2006084474
	Date:	17.08.2006
	Language:	EN
	[2006/33]
	Type:	A2 Application without search report
	No.:	EP1853249
	Date:	14.11.2007
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 17.08.2006 takes the place of the publication of the European patent application.
	[2007/46]
Search report(s)	International search report - published on:	EP	02.11.2006
Classification	IPC:	A61K31/216, A61K31/366, A61K31/40, A61K9/16, A61K9/24, A61K9/26	[2007/46]
	CPC:	A61K45/06 (EP,US); A61K9/20 (KR); A61K31/216 (EP,US); A61K31/366 (EP,US); A61K31/40 (EP,KR,US); A61K9/16 (KR); (+) A61K9/209 (EP,KR,US); A61P43/00 (EP) (-)
	C-Set:	A61K31/216, A61K2300/00 (EP,US); A61K31/366, A61K2300/00 (US,EP); A61K31/40, A61K2300/00 (US,EP)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2007/46]
Extension states	AL	10.09.2007
	BA	10.09.2007
	HR	10.09.2007
	MK	10.09.2007
	YU	10.09.2007
Title	German:	STABILE PHARMAZEUTISCHE ZUSAMMENSETZUNG AUS EINER FIXDOSEN-KOMBINATION VON FENOFIBRAT UND EINEM HMG-COA-REDUCTASE-HEMMER	[2007/46]
	English:	A STABLE PHARMACEUTICAL COMPOSITION COMPRISING A FIXED DOSE COMBINATION OF FENOFIBRATE AND AN HMG-COA REDUCTASE INHIBITOR	[2007/46]
	French:	PREPARATION PHARMACEUTIQUE STABLE COMPRENANT UNE DOSE FIXE DE FENOFIBRATE ET D'UN INHIBITEUR DE LA HMG-COA REDUCTASE	[2007/46]
Entry into regional phase	10.09.2007	National basic fee paid
	10.09.2007	Designation fee(s) paid
	10.09.2007	Examination fee paid
Examination procedure	28.08.2007	Amendment by applicant (claims and/or description)
	10.09.2007	Examination requested [2007/46]
	20.12.2007	Despatch of a communication from the examining division (Time limit: M08)
	16.12.2008	Reply to a communication from the examining division
	19.01.2009	Despatch of a communication from the examining division (Time limit: M06)
	10.11.2009	Reply to a communication from the examining division
	03.09.2013	Application deemed to be withdrawn, date of legal effect [2014/06]
	27.09.2013	Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2014/06]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 20.12.2007
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	16.12.2008	Request for further processing filed
	16.12.2008	Full payment received (date of receipt of payment) Request granted
	07.01.2009	Decision despatched
Fees paid	Renewal fee
	29.02.2008	Renewal fee patent year 03
	02.03.2009	Renewal fee patent year 04
	01.03.2010	Renewal fee patent year 05
	28.02.2011	Renewal fee patent year 06
	29.02.2012	Renewal fee patent year 07
	Penalty fee
	Additional fee for renewal fee
	28.02.2013	08 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[E]WO2006037348 (LIFECYCLE PHARMA AS [DK], et al) [E] 1-48,1-48,1-48 * paragraph [0293] - paragraph [0310] * * paragraph [0319] - paragraph [0369] * * paragraph [0293] - paragraph [0310] * * paragraph [0319] - paragraph [0369] * * paragraph [0293] - paragraph [0310] * * paragraph [0319] - paragraph [0369] *;
		[E]WO2006037344 (LIFECYCLE PHARMA AS [DK], et al) [E] 1-48,1-48,1-48 * paragraph [0289] - paragraph [0306] * * paragraph [0317] - paragraph [0347] * * paragraph [0289] - paragraph [0306] * * paragraph [0317] - paragraph [0347] * * paragraph [0289] - paragraph [0306] * * paragraph [0317] - paragraph [0347] *;
		[X]WO0037078 (BAYER AG [DE], et al) [X] 1-48,1-48,1-48 * examples 3,4 * * examples 3,4 * * examples 3,4 *;
		[X]EP0455042 (SQUIBB & SONS INC [US]) [X] 1-48,1-48,1-48 * page 5, lines 27,28 * * page 5, lines 27,28 * * page 5, lines 27,28 *;
		[X]EP0475148 (SQUIBB & SONS INC [US]) [X] 1-48,1-48,1-48 * example 3 * * example 3 * * example 3 *;
		[X]WO03013608 (GALEPHAR M F [BE], et al) [X] 1-48,1-48,1-48 * example 3 * * example 3 * * example 3 *;
		[X]WO0224169 (RTP PHARMA INC [US]) [X] 1-48,1-48,1-48 * page 53, line 8 - line 9 * * page 53, line 27 * * page 54, line 9 * * page 55, line 23 - line 25 * * page 53, line 8 - line 9 * * page 53, line 27 * * page 54, line 9 * * page 55, line 23 - line 25 * * page 53, line 8 - line 9 * * page 53, line 27 * * page 54, line 9 * * page 55, line 23 - line 25 *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p